Seagen Inc. (NASDAQ:SGEN – Get Free Report) EVP Charles R. Romp sold 555 shares of the firm’s stock in a transaction that occurred on Thursday, August 31st. The stock was sold at an average price of $206.97, for a total transaction of $114,868.35. Following the completion of the transaction, the executive vice president now directly owns 69,156 shares in the company, valued at $14,313,217.32. The transaction was disclosed in a document filed with the SEC, which is available through this link.
Seagen Stock Performance
Seagen stock opened at $207.91 on Friday. The company has a market capitalization of $39.02 billion, a PE ratio of -53.45 and a beta of 0.50. Seagen Inc. has a fifty-two week low of $116.08 and a fifty-two week high of $210.50. The firm has a 50 day moving average price of $195.59 and a 200 day moving average price of $193.82.
Seagen (NASDAQ:SGEN – Get Free Report) last issued its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($1.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.35). Seagen had a negative net margin of 33.54% and a negative return on equity of 26.46%. The firm had revenue of $603.83 million during the quarter, compared to analyst estimates of $555.68 million. As a group, equities research analysts forecast that Seagen Inc. will post -3.4 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Read Our Latest Stock Report on Seagen
Institutional Trading of Seagen
Institutional investors and hedge funds have recently bought and sold shares of the business. Norges Bank acquired a new position in shares of Seagen in the fourth quarter valued at approximately $281,065,000. Barclays PLC boosted its position in Seagen by 836.5% in the 2nd quarter. Barclays PLC now owns 2,069,120 shares of the biotechnology company’s stock valued at $398,222,000 after buying an additional 1,848,180 shares during the period. BlackRock Inc. increased its position in shares of Seagen by 7.6% during the second quarter. BlackRock Inc. now owns 12,041,819 shares of the biotechnology company’s stock worth $2,317,568,000 after acquiring an additional 850,697 shares during the period. Renaissance Technologies LLC raised its stake in shares of Seagen by 7,830.0% in the second quarter. Renaissance Technologies LLC now owns 848,513 shares of the biotechnology company’s stock valued at $163,305,000 after acquiring an additional 837,813 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its stake in shares of Seagen by 76.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,580,816 shares of the biotechnology company’s stock valued at $320,069,000 after acquiring an additional 685,883 shares in the last quarter. 84.26% of the stock is currently owned by hedge funds and other institutional investors.
About Seagen
Seagen Inc, a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer.
Featured Articles
- Five stocks we like better than Seagen
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- MarketBeat Week in Review – 8/28 – 9/1
- Consumer Discretionary Stocks Explained
- 2 Stocks That Doubled EPS Estimates and Flashing Buy Signals
- How to Invest in E-Commerce: A Guide
- Toyota vs Tesla: The Tortoise And The Hare Race Has A New Meaning
Receive News & Ratings for Seagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seagen and related companies with MarketBeat.com's FREE daily email newsletter.
